Rodman & Renshaw Archives - Page 41 of 44

MondayNov 03, 2008 4:06 am

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE)

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE) is focused on developing therapeutic and diagnostic products designed mainly for disorders in the central nervous system. The company’s robust molecular imaging development program targets the diagnosis of Parkinson's disease and potentially dementia. Altropane, the company's lead molecular imaging product candidate, is currently in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes, including Parkinson's Disease. For further information, visit the Company's web site at www.alseres.com.

MondayNov 03, 2008 4:05 am

Lotus Pharmaceuticals Inc. (OTC BB: LTUS)

Lotus Pharmaceuticals Inc. (OTC BB: LTUS) is becoming one of China’s leaders in the marketing of prescription and over the counter medications. Lotus develops high quality, low cost generic medication and other over the counter brands. Led by their CEO Dr. Liu Zhongyi, the company expects to have continued growth of 20% per year and yearly revenues of over $140 million. For further information, visit the company website at: www.lotuseast.com.

MondayNov 03, 2008 4:05 am

Alphatec Spine, Inc. (NASDAQ: ATEC)

Alphatec Spine, Inc. (NASDAQ: ATEC), a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC), is focused on designing, developing, manufacturing and marketing products for the surgical treatment of spine disorders. The company aims to combine world-class customer service with innovative, surgeon-driven design to help improve the aging patient's quality of life. By using innovative solutions, Alphatec well positioned to accomplish its goal. For further information, visit the Company's web site at www.alphatecspine.com.

MondayNov 03, 2008 4:04 am

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a biopharmaceutical company, is focused on developing novel therapeutics based on RNA interference, or RNAi. By applying its therapeutic expertise in RNAi, the company intends to address substantial medical needs, many of which cannot be effectively addressed with small molecules or antibodies, the current major classes of drugs. Alnylam has taken a leadership role in the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. For further information, visit the Company's web site at www.alnylam.com.

MondayNov 03, 2008 4:04 am

Lorus Therapeutics, Inc. (AMEX: LRP)

Lorus Therapeutics, Inc. (AMEX: LRP), a biopharmaceutical company, is focused on discovering, researching and developing effective anticancer therapies with high safety profiles. By utilizing its own discovery efforts, in addition to acquisition and in-licensing programs, the company is building a portfolio of anticancer drugs ranging from discovery and preclinical to an advanced Phase II clinical trial. Each of the drug candidates in their current pipeline are backed by a strong intellectual property portfolio. For further information, visit the Company's web site at www.lorusthera.com.

MondayNov 03, 2008 4:03 am

LightPath Technologies, Inc. (NASDAQ: LPTH)

LightPath Technologies, Inc. (NASDAQ: LPTH) is a recognized leader in optical solutions for industrial, defense, communications, test and measurement, and medical applications. With unique products such as Black Diamond Infrared Lenses and Gradium Lenses, LightPath Technologies is shedding light in the field of optical solutions. For further information, visit the company website at: www.lightpath.com.

MondayNov 03, 2008 4:03 am

Allos Therapeutics, Inc. (NASDAQ: ALTH)

Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company's lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company's web site at www.allos.com.

MondayNov 03, 2008 4:03 am

LCA-Vision, Inc. (NASDAQ: LCAV)

LCA-Vision, Inc. (NASDAQ: LCAV) provides laser vision correction services under its well known Lasik Plus brand. The company currently owns and operates over 70 LasikPlus fixed-site laser vision correction centers in the United States and a joint venture in Canada. These laser correction centers are staffed with experienced ophthalmologists, optometrists and other healthcare professionals. To date, the company has performed more than a million vision correction procedures. For further information, visit the Company's web site at www.lcavision.com.

MondayNov 03, 2008 4:03 am

Alhambra Resources Ltd. (TSX: ALH CN)

Alhambra Resources Ltd. (TSX: ALH CN), a Canadian based exploration and gold production corporation, operates through its wholly owned subsidiary, Saga Creek Gold Corp LLP ("Saga Creek"). The company holds the rights to two Licenses that have an initial term of 25 years granted by the Republic of Kazakhstan in 1997. These two Licenses are the subject of an exploration and exploitation Contract between Saga Creek and the Republic of Kazakhstan, and will not expire until the year 2022. For further information, visit the Company's web site at www.alhambraresources.com.

MondayNov 03, 2008 4:02 am

LAURION Mineral Exploration Inc. (TSX: LME CN)

LAURION Mineral Exploration Inc. (TSX: LME CN), an exploration company, has its focus on discovering multiple, high-impact project, from gold projects to base metals and PGE’s. The company has key interests in highly prospective properties and aims to achieve long-term growth by making sound business decisions, creating strategic alliances with companies that have high technical expertise, and strategically target well positioned projects in geological systems where discoveries have been repetitive. For further information, visit the Company's web site at www.laurion.ca.

Site Search

Company Search

Tag: Rodman & Renshaw

Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE)

Lotus Pharmaceuticals Inc. (OTC BB: LTUS)

Alphatec Spine, Inc. (NASDAQ: ATEC)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Lorus Therapeutics, Inc. (AMEX: LRP)

LightPath Technologies, Inc. (NASDAQ: LPTH)

Allos Therapeutics, Inc. (NASDAQ: ALTH)

LCA-Vision, Inc. (NASDAQ: LCAV)

Alhambra Resources Ltd. (TSX: ALH CN)

LAURION Mineral Exploration Inc. (TSX: LME CN)

Market Basics

Newsletter Publishers

Public Companies